ResMed, Inc. is a company that focuses on developing, manufacturing, and marketing products for diagnosing, treating, and managing respiratory diseases, specifically sleep-disordered breathing.

The company's net sales come from three main product families: medical devices (50.4% of sales), masks (37.9% of sales), and software as a service (11.7% of sales).

ResMed operates six production sites globally, including two in the United States, as well as facilities in Australia, China, Singapore, and Malaysia.

The United States is a significant market for the company, accounting for 61.4% of its net sales.

UBS has a neutral stance on ResMed, reflecting the company's stable position in the respiratory health sector.